No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

SafeSite Takes On COVID-19 with Protocol-Oriented Testing

Editor: What To Know

  • Beyond a bubble environment, venue setting or group use case, SafeSite-PASS can eventually be used in the general community as evidence of an individual's health status as well as an effective and productive tracking and tracing tool.
  • “There is an immediate need from the community level all the way to nationwide partners for a protocol that is mobile facilities-based, repetitive, and rapid in response.
  • It is essential to apply multiple diagnostic methods, using the most rigorous FDA-approved tests in combination with an appropriate protocol to safely and confidently reopen schools, companies, sports and entertainment venues,” said Sexton.

September 10, 2020

SafeSite, the medical diagnostic, mobile laboratory company, has scaled its west coast-based testing model nationally to help schools, universities, and businesses safely and responsibly reopen. Working with new logistics partner Live Media Group, SafeSite will expand its deployment of mobile laboratories that perform rapid response COVID-19 testing, along with a data-driven personal tracking and contact tracing platform.

SafeSite was formed by an assembly of medical professionals, all frustrated with the lack of cohesive and reliable COVID-19 testing procedures. SafeSite CEO Lauren Rogen Sexton sees an opportunity to change this through a truly protocol-oriented approach that provides results in less than one hour.

SafeSite’s protocol-oriented approach includes creating custom on-site mobile laboratories that give medical personnel a secure environment to administer tests and yield conclusive diagnoses. Applying a multi-pronged approach, SafeSite uses multiple diagnostic methodologies, employing RT-PCR, isothermal amplification, and antigen tests. Results are produced on-site in less than one hour, eliminating the risk of an attendee’s exposure between testing and arrival to alocation or venue.

“There is an immediate need from the community level all the way to nationwide partners for a protocol that is mobile facilities-based, repetitive, and rapid in response. After listening for months to advice from a number of medical and industry experts, including Bill Gates, I took it upon myself to do something instead of sitting ideally by waiting for an effective plan. It is essential to apply multiple diagnostic methods, using the most rigorous FDA-approved tests in combination with an appropriate protocol to safely and confidently reopen schools, companies, sports and entertainment venues,” said Sexton.

The company’s propriety technology platform, SafeSite-PASS, is used by each organization and individual, providing QR Code-based touchless functionality with historical data of all test results stored within user profiles. SafeSite-PASS is a valuable resource for organizations seeking a HIPAA-compliant mobile technology for health monitoring that securely delivers a COVID-19-free business, school or venue location. Beyond a bubble environment, venue setting or group use case, SafeSite-PASS can eventually be used in the general community as evidence of an individual’s health status as well as an effective and productive tracking and tracing tool.

Live Media Group is a natural partner for SafeSite given its extensive corporate, sports and entertainment production expertise, mobile facilities, and logistics experience. This will help SafeSite meet the demand from many clients and verticals, beyond its existing west coast region and headquarters and direct to more populations throughout the United States.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy